Aridis is discovering and developing highly differentiated drug candidates to prevent and treat life-threatening infectious diseases that overcome the threat of AMR and global viral outbreaks, with both therapeutic monoclonal antibodies and novel anti-infectives designed to complement the current standards of care.
- Hospital Acquired Infections (Ventilator Associated Pneumonia)
- Cystic Fibrosis
- Blood Stream Infections
- COVID-19 viral infection